Skip to main content
    S

    Surrozen Inc (SRZN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $32.32
    +0.71 (+2.25%)

    Market Cap: $602.54M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Surrozen Inc (SRZN) Financials: Revenue, Profit and Cash Flow

    Updated Nov 9, 2026. Financial statements from company filings, amounts in US dollars.

    Surrozen reported revenue of $3.48M for the fiscal year ended Dec 31, 2025, down 67.4% from the year before. That year, net income was -$242.03M with a net margin of -6960.8%, operating cash flow was -$30.24M and free cash flow was -$30.37M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$129.72M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$3.48M-67.4%100.0%-1210.6%-6960.8%
    Dec 2024$10.65MN/A100.0%-239.7%-596.6%
    Dec 2023$0-100.0%N/AN/AN/A
    Dec 2022$12.50MN/A100.0%-354.7%-288.0%
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$3.48M$10.65M$0$12.50M$0$0N/A
    Gross profit$3.48M$10.65M$0$12.50M$0$0N/A
    Research and development$29.36M$21.13M$27.23M$37.01M$40.18M$25.68M$19.60M
    Operating income-$42.09M-$25.54M-$45.78M-$44.34M-$54.39M-$32.81M-$25.11M
    Net income-$242.03M-$63.56M-$43.04M-$36.00M-$54.65M-$32.72M-$24.36M
    EBITDAN/AN/A-$44.60M-$34.72M-$52.55M-$30.87M-$22.82M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$5.00M$5.00M$528.00K$983.00K$983.00K$983.00K$655.00K$10.00M$0$0$0
    Gross profit$0$5.00M$5.00M$528.00K$983.00K$983.00K$983.00K$655.00K$10.00M$0$0N/A
    Operating income-$17.64M-$10.37M-$10.46M-$12.64M-$10.88M-$9.02M-$9.55M-$8.59M$1.23M-$9.05M-$9.13M-$9.72M
    Net income-$129.72M$50.18M-$127.50M-$183.16M-$71.64M$39.75M-$26.97M-$48.44M-$1.43M-$4.86M-$8.83M-$8.91M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $1.29M by $87.95M. Shareholder equity was negative, at -$187.76M, as total liabilities of $286.49M exceeded total assets of $98.73M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$98.73M$48.47M$46.08M$89.44M$137.17M$62.06M$42.48M
    Current assets$91.56M$38.93M$41.13M$81.31M$105.19M$50.22M$29.41M
    Cash and equivalents$89.25M$34.56M$36.04M$24.69M$33.09M$34.98M$29.10M
    Total liabilities$286.49M$69.85M$8.14M$13.43M$27.47M$14.77M$13.10M
    Short-term debt$1.29M$1.83M$2.50M$2.23M$2.19M$2.11M$1.50M
    Shareholder equity-$187.76M-$21.38M$37.94M$76.00M$109.70M$47.29M$29.39M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$109.03M$115.61M$120.71M$98.73M$94.05M$102.70M$114.83M$48.47M$48.00M$45.07M$36.72M$46.08M
    Total liabilities$444.66M$334.27M$398.86M$286.49M$117.56M$55.58M$109.16M$69.85M$42.33M$39.01M$6.58M$8.14M
    Cash and equivalents$100.35M$102.04M$106.91M$89.25M$81.33M$90.39M$101.64M$34.56M$31.01M$37.77M$27.29M$36.04M
    Shareholder equity-$335.62M-$218.66M-$278.15M-$187.76M-$23.52M$47.11M$5.67M-$21.38M$5.67M$6.06M$30.14M$37.94M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$30.24M-$17.63M-$40.36M-$44.15M-$48.81M-$29.10M-$21.06M
    Capital expenditures$128.00K$26.00K$398.00K$728.00K$1.27M$874.00K$1.56M
    Free cash flow-$30.37M-$17.65M-$40.76M-$44.87M-$50.08M-$29.97M-$22.62M
    Dividends paidN/AN/AN/AN/AN/A$48.39MN/A
    Share repurchasesN/AN/AN/A$2.69M$0N/AN/A
    Investing cash flow-$128.00K-$26.00K$51.72M$38.31M-$77.71M-$15.07M-$1.56M
    Financing cash flow$85.05M$16.18M$276.00K-$2.56M$124.63M$50.05M$28.90M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$4.83M-$7.42M-$12.49M-$5.81M-$9.04M-$6.11M-$9.28M$3.48M-$6.75M-$5.61M-$8.75M-$7.31M
    Capital expenditures$27.00K$19.00K$120.00K$59.00K$24.00K$18.00K$27.00K$19.00K$0$0$7.00K$0
    Free cash flow-$4.86M-$7.43M-$12.62M-$5.87M-$9.06M-$6.13M-$9.31M$3.46M-$6.75M-$5.61M-$8.75M-$7.31M
    Last 12 quarters

    Frequently Asked Questions About SRZN

    What is Surrozen's annual revenue?

    Surrozen reported revenue of $3.48M for the fiscal year ended Dec 31, 2025.

    How fast is Surrozen's revenue growing?

    Revenue was down 67.4% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Surrozen profitable?

    No. Surrozen reported net income of -$242.03M for the fiscal year ended Dec 31, 2025, with a net margin of -6960.8%.

    How much free cash flow does SRZN generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$30.24M minus capital expenditures of $128.00K produced free cash flow of -$30.37M.

    How much debt does Surrozen have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $1.29M and cash and equivalents of $89.25M.